{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:02Z","timestamp":1760297042460},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":5839,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1093\/annonc\/mdh003","type":"journal-article","created":{"date-parts":[[2003,12,20]],"date-time":"2003-12-20T02:42:52Z","timestamp":1071888172000},"page":"161-171","source":"Crossref","is-referenced-by-count":27,"title":["Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors"],"prefix":"10.1016","volume":"15","author":[{"given":"K.","family":"Vera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Djafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-S.","family":"Guillamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Djazouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cioloca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Abdulkarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Armand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh003_bb0010","first-page":"1769","article-title":"Activity of temozolomide against human tumor colony-forming units","volume":"3","author":"Raymond","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0015","first-page":"5846","article-title":"Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045: M&B39831), a novel drug with potential as an alternative to dacarbazine","volume":"47","author":"Stevens","year":"1987","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0020","first-page":"2585","article-title":"Temozolomide and treatment of malignant glioma","volume":"6","author":"Friedman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0025","first-page":"2725","article-title":"Multifaceted resistance of gliomas to temozolomide","volume":"8","author":"Bocangel","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0030","first-page":"2908","article-title":"Pharmacologic disruption of base excision repair sensitises mismatch repair-deficient and -proficient colon cancer cells to methylating agents","volume":"5","author":"Liu","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0035","first-page":"5843","article-title":"Abrogation of Chk1-mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53 independent manner in human glioblastoma cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0045","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","article-title":"Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma","volume":"13","author":"Bleehen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0050","first-page":"940","article-title":"Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [published erratum appears in Eur J Cancer 1993; 29A: 1500]","volume":"29A","author":"O\u2019Reilly","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0055","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.1999.17.8.2604","article-title":"Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies","volume":"17","author":"Hammond","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0060","first-page":"1093","article-title":"Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer","volume":"3","author":"Dhodapkar","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0065","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","article-title":"Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules","volume":"88","author":"Tolcher","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0070","first-page":"4363","article-title":"Phase I trial of temozolomide using an extended continuous oral schedule","volume":"58","author":"Brock","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh003_bb0075","first-page":"222a","article-title":"Protracted daily administration of temozolomide is feasible a phase I and pharmacokineticpharmacodynamic study","author":"Denis","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0080","first-page":"222a","article-title":"Protracted cyclic administration of temozolomide is feasible; a phase I pharmacokinetic and pharmacodynamic study","author":"Figueroa","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0085","first-page":"667","article-title":"Response to temozolomide in recurrent high grade gliomas is related to tumour drug concentration","volume":"9","author":"Brock","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0090","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.1999.17.8.2604","article-title":"Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies","volume":"17","author":"Hammond","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","article-title":"Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies","volume":"81","author":"Brada","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1022592913323","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates","volume":"61","author":"Patel","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdh003_bb0105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"MacDonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdh003_bb0115","series-title":"Antineoplastic and Immunosuppressive Agents","first-page":"553","article-title":"Triazenoimidazole derivatives","author":"Loo","year":"1975"},{"key":"10.1093\/annonc\/mdh003_bb0120","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/bi00197a003","article-title":"NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA","volume":"33","author":"Denny","year":"1994","journal-title":"Biochemistry"},{"key":"10.1093\/annonc\/mdh003_bb0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s002800050427","article-title":"Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase","volume":"37","author":"Belanich","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdh003_bb0130","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.1998.16.12.3851","article-title":"DNA mismatch repair and O6-aklylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma","volume":"16","author":"Friedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0135","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh003_bb0140","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/bjc.1996.85","article-title":"Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro","volume":"73","author":"Wedge","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0150","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","article-title":"Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma","volume":"13","author":"Bleehen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0155","first-page":"940","article-title":"Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [published erratum appears in Eur J Cancer 1993; 29A: 1500]","volume":"29A","author":"O\u2019Reilly","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s002800050691","article-title":"Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma","volume":"40","author":"Bower","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdh003_bb0165","article-title":"Phase II study of temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients","volume":"16","author":"Levin","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0170","article-title":"Temozolomide in high grade gliomas at second relapse a phase II study","volume":"19","author":"Brandes","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0175","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2001.19.9.2449","article-title":"Safety and efficacy of Temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy","volume":"19","author":"Chinot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0180","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0959-8049(96)00258-4","article-title":"The Charing Cross Hospital experience with temozolomide in patients with gliomas","volume":"32A","author":"Newlands","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0185","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group [published erratum appears in J Clin Oncol 1999; 17: 3693]","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0190","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.1998.16.12.3851","article-title":"DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma","volume":"16","author":"Friedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicentre phase II trial of temozolomide in patients with GBM at first relapse","volume":"12","author":"Brada","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh003_bb0200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh003_bb0205","first-page":"264","article-title":"Preradiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide","volume":"2","author":"Gilbert","year":"2000","journal-title":"Neurooncol"},{"key":"10.1093\/annonc\/mdh003_bb0210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdg157","article-title":"Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972","volume":"14","author":"Van den Bent","year":"2003","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419615188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419615188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/1\/161\/332069\/mdh003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T01:23:44Z","timestamp":1582248224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419615188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0923753419615188"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh003","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}